Tag archive for ‘Samsung Bioepis’
By news On Thursday, April 5th, 2018

AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023

(adsbygoogle = window.adsbygoogle || []).push({}); (Reuters) – AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off More...

By news On Tuesday, February 13th, 2018

Drug copies ready to take next bite out of Roche’s cancer sales

LONDON (Reuters) – European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies More...

By news On Friday, August 25th, 2017

Samsung, Biogen version of AbbVie’s Humira approved in Europe

(Reuters) – A biosimilar version of AbbVie Inc’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics, was approved by European Union regulators, the partners More...

By news On Monday, July 24th, 2017

Merck, Samsung Bioepis launch discounted U.S. Remicade alternative

NEW YORK/SEOUL (Reuters) – Merck & Co and South Korea’s Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson’s rheumatoid More...